Opinion|Videos|July 24, 2024
Ensuring PNH Treatment Access and Adherence to Therapies
Barriers to care and treatment adherence for patients diagnosed with PNH is discussed.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What strategies can effectively ensure seamless access to therapies (eg, partnering with specialized pharmacies for dispensing)?
- When considering treatment options, how do factors related to supporting and enhancing adherence influence your choice of therapy? Could you discuss the opportunities and approaches you leverage to promote optimal treatment adherence in this patient population?
Advertisement
Related to this article
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.
Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5